Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled pediatric upadacitinib study in severe alopecia areata
MOH_2026-10-04_017061Phase 3Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in alopecia areata (5 arms), sponsored by AbbVie Inc. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
upadacitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on MOH_2026-10-04_017061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-10-04_017061.